• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2024年5月老年人血清中针对新冠病毒KP.3.1.1和XEC的中和抗体水平较低。

Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024.

作者信息

Fossum Even, Vikse Elisabeth Lea, Robertson Anna Hayman, Wolf Asia-Sophia, Rohringer Andreas, Trogstad Lill, Mjaaland Siri, Hungnes Olav, Bragstad Karoline

机构信息

Department of Virology, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.

Department of Method Development and Analytics, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.

出版信息

Influenza Other Respir Viruses. 2025 May;19(5):e70102. doi: 10.1111/irv.70102.

DOI:10.1111/irv.70102
PMID:40369880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12078752/
Abstract

New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study, we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that were either widely distributed or on the rise globally in the fall of 2024, in sera from a cohort of seniors aged 68-82 years collected in April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, also in XBB.1.5 boosted individuals and people with recent break-through infections, supporting the recommendation of an updated COVID-19 vaccine booster in this age group.

摘要

新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫逃逸变体可能会增加老年等风险人群的感染率和住院率。在本研究中，我们评估了2024年4月/5月收集的68 - 82岁老年人群队列血清中针对KP.3.1.1和XEC的中和抗体，这两种病毒变体在2024年秋季全球范围内广泛传播或呈上升趋势。在XBB.1.5加强免疫的个体和近期有突破性感染的人群中，针对KP.3.1.1和XEC的中和反应均较低，这支持了在该年龄组中更新新冠病毒疫苗加强针的建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/facc/12078752/5748ce85967e/IRV-19-e70102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/facc/12078752/5748ce85967e/IRV-19-e70102-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/facc/12078752/5748ce85967e/IRV-19-e70102-g001.jpg

相似文献

1
Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024.2024年5月老年人血清中针对新冠病毒KP.3.1.1和XEC的中和抗体水平较低。
Influenza Other Respir Viruses. 2025 May;19(5):e70102. doi: 10.1111/irv.70102.
2
mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.适应于JN.1或KP.2的mRNA-1273疫苗在小鼠中引发针对新冠病毒JN.1亚谱系的交叉中和反应。
Vaccine. 2025 Apr 30;54:126961. doi: 10.1016/j.vaccine.2025.126961. Epub 2025 Mar 7.
3
Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability.新型冠状病毒XEC变异株N端结构域糖基化突变在免疫逃逸、细胞间融合及刺突蛋白稳定性中的作用
J Virol. 2025 Apr 15;99(4):e0024225. doi: 10.1128/jvi.00242-25. Epub 2025 Mar 26.
4
Neutralizing antibody responses to three XBB protein vaccines in older adults.老年人对三种XBB蛋白疫苗的中和抗体反应。
Signal Transduct Target Ther. 2025 Feb 3;10(1):48. doi: 10.1038/s41392-025-02132-y.
5
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.重组XBB.1.5加强针可诱导对包括KP.2和KP.3在内的JN.1亚谱系产生强大的中和作用。
Signal Transduct Target Ther. 2025 Jan 27;10(1):47. doi: 10.1038/s41392-025-02139-5.
6
Comparable immune escape capacity between KP.2 and other SARS-CoV-2 variants in the central Chinese population after the first COVID-19 booster.在中国中部人群中，首次接种新冠疫苗加强针后，KP.2与其他新冠病毒变异株之间具有相当的免疫逃逸能力。
Sci Rep. 2025 May 22;15(1):17762. doi: 10.1038/s41598-025-02927-7.
7
Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients.奥密克戎变种JN.1、KP.2和KP.3对新冠康复者及疫苗接种者的多克隆和单克隆抗体的免疫逃逸
Antiviral Res. 2025 Mar;235:106092. doi: 10.1016/j.antiviral.2025.106092. Epub 2025 Jan 27.
8
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.XBB.1.5 rS 疫苗在叙利亚仓鼠中针对 SARS-CoV-2 的 EG.5.1 变异株的免疫原性和疗效。
J Virol. 2024 Oct 22;98(10):e0052824. doi: 10.1128/jvi.00528-24. Epub 2024 Sep 4.
9
Fc-effector functional antibody assays for SARS-CoV-2 variants of concern.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关注变异株的Fc效应器功能抗体检测
Front Immunol. 2025 May 20;16:1571835. doi: 10.3389/fimmu.2025.1571835. eCollection 2025.
10
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies.XBB.1.5单价疫苗可诱导对SARS-CoV-2变体（如HV.1和JN.1）以及SARS-CoV-1产生持久的交叉反应，但产生的XBB.1.5特异性抗体有限。
mBio. 2025 Apr 9;16(4):e0360724. doi: 10.1128/mbio.03607-24. Epub 2025 Mar 5.

引用本文的文献

1
The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.XEC变体：基因组进化、免疫逃逸及对公共卫生的影响
Viruses. 2025 Jul 15;17(7):985. doi: 10.3390/v17070985.

本文引用的文献

1
Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data.丹麦、芬兰和瑞典含单价XBB.1.5的新冠mRNA疫苗的比较有效性：基于登记数据的目标试验模拟
BMJ Med. 2024 Nov 17;3(1):e001074. doi: 10.1136/bmjmed-2024-001074. eCollection 2024.
2
Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株KP.3.1.1和XEC通过N端结构域突变增强免疫逃逸
Lancet Infect Dis. 2025 Jan;25(1):e6-e7. doi: 10.1016/S1473-3099(24)00738-2. Epub 2024 Nov 22.
3
Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera.
人源和鼠源血清对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）KP.1、KP.1.1、KP.2和KP.3的中和作用。
NPJ Vaccines. 2024 Nov 11;9(1):215. doi: 10.1038/s41541-024-01016-6.
4
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.2023 年 11 月 20 日至 2024 年 3 月 1 日期间，在 JN.1 谱系占主导地位期间，针对老年人的 XBB.1.5 疫苗对有症状的 SARS-CoV-2 感染的有效性，欧洲 VEBIS 初级保健多中心研究。
Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009.
5
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.JN.1加强疫苗接种对SARS-CoV-2变异株KP.3.1.1和XEC中和作用的影响
Lancet Infect Dis. 2024 Dec;24(12):e732-e733. doi: 10.1016/S1473-3099(24)00688-1. Epub 2024 Nov 7.
6
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.T 细胞对接受 TNF 抑制剂治疗的患者反复接种 SARS-CoV-2 疫苗和突破性感染的反应：一项前瞻性队列研究。
EBioMedicine. 2024 Oct;108:105317. doi: 10.1016/j.ebiom.2024.105317. Epub 2024 Sep 10.
7
Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.2022 年夏末挪威的 SARS-CoV-2 抗体特征：所有年龄段的血清阳性率都很高，儿童中主要为奥密克戎感染模式，成人中为混合免疫。
BMC Infect Dis. 2024 Aug 20;24(1):841. doi: 10.1186/s12879-024-09670-w.
8
Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）KP.3.1.1变异株的病毒学特征。
Lancet Infect Dis. 2024 Oct;24(10):e609. doi: 10.1016/S1473-3099(24)00505-X. Epub 2024 Aug 16.
9
SARS-CoV-2 correlates of protection from infection against variants of concern.SARS-CoV-2 对感染关切变异株的保护相关因素。
Nat Med. 2024 Oct;30(10):2805-2812. doi: 10.1038/s41591-024-03131-2. Epub 2024 Jul 26.
10
In-hospital mortality during the wild-type, alpha, delta, and omicron SARS-CoV-2 waves: a multinational cohort study in the EuCARE project.野生型、阿尔法、德尔塔和奥密克戎新冠病毒毒株流行期间的院内死亡率：EuCARE项目中的一项多国队列研究
Lancet Reg Health Eur. 2024 Feb 2;38:100855. doi: 10.1016/j.lanepe.2024.100855. eCollection 2024 Mar.